Novartis’ Fabhalta (iptacopan) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat paroxysmal nocturnal haemoglobinuria (PNH) in adults with haemolytic ...

See the committee papers for full details of the evidence. Paroxysmal nocturnal haemoglobinuria (PNH) is a rare blood condition caused by an acquired mutation of the PIG‑A gene within bone marrow stem ...

Roche's PiaSky has been approved by the European Commission, becoming the first therapy for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by monthly subcutaneous ...

In his opening speech, Haman Zachari, Representative of the Office of the High Commissioner for Human Rights (OHCHR), said he hoped to strengthen the capacity of the specialized units of the Haitian ...

The Haitian National Police (PNH) recently launched an awareness and blood collection campaign at the National Police School, aimed at setting up a blood bank within the Police Institution, an ...

Friday, September 6, 2024, on the instructions of Rameau Normil, Commander of the National Police of Haiti (PNH), the Croix-des-Bouquets Police, accompanied by agents of the Departmental Unit for ...

Zaltenibart is under clinical development by Omeros and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase II drugs for Paroxysmal Nocturnal Hemoglobinuria ...

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...

Roche’s PiaSky is the first monthly subcutaneous therapy for PNH approved in the European Union. Credit: Poetra.RH/Shutterstock. The European Commission (EC) has approved Roche’s recycling monoclonal ...